In this article, we will be taking a look at the 11 Best Growth Stocks to Buy and Hold Forever.Global equities are likely to continue edging higher even as valuation concerns continue to arouse fear among investors. A survey by Bank of America of global fund managers indicates that most of them remain overweight equities. Likewise, opinions about growth have improved significantly, with only 16% of economists expecting the economy to weaken.The survey underscores the bullish thesis in the equity markets as ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by DexCom, Inc. following allegations from a short report that highlighted serious issues with the company's G7 glucose monitoring system [1][3]. Group 1: Allegations and Impact - Hunterbrook Media published a report titled "Dexcom's Fatal Flaws," claiming that DexCom made unauthorized design changes to a critical component of the G7 system, leading to hospitalizations and fatalities due to inaccurate glucose readings [3]. - Following the release of the Hunterbrook report, DexCom's stock price dropped by $8.99 per share, representing an 11.76% decline, closing at $67.45 per share on September 19, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking to represent investors of DexCom who may have been affected by the alleged misconduct, urging them to come forward [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].

Group 1 - Significant bearish sentiment among deep-pocketed investors towards DexCom, with 67% of options activity being bearish and only 24% bullish [1][2] - Notable options activity includes 44 puts totaling $5,335,067 and 9 calls amounting to $566,792, indicating a strong preference for bearish positions [2] - Projected price targets for DexCom range from $60.0 to $135.0 based on recent trading activity [3] Group 2 - The mean open interest for DexCom options trades is 1461.65, with a total volume of 61,242.00, reflecting significant liquidity and interest [4] - Recent options activity shows a mix of bullish and bearish trades, with notable bearish trades including puts with strike prices around $77.00 [10] - Current market status indicates a trading volume of 14,874,989 and a price decline of -11.34%, with the stock currently priced at $67.19 [15] Group 3 - DexCom specializes in continuous glucose monitoring systems for diabetic patients, evolving its products to integrate with insulin pumps for automatic insulin delivery [11] - Analysts have proposed an average target price of $100.0 for DexCom, reflecting a cautious outlook [12][13] - The next earnings report for DexCom is scheduled in 34 days, which may influence market sentiment [15]

Core Viewpoint - Dividend cuts can present investment opportunities, as the negative news is often already priced in, leading to potential undervaluation of assets [3][7]. Group 1: Market Reactions to Dividend Cuts - Wall Street analysts and individual investors often react negatively to dividend cuts, leading to knee-jerk selling of affected funds [2][3]. - BlackRock Health Sciences Term Trust (BMEZ) experienced a dividend cut, prompting some investors to sell, but this creates opportunities for contrarian investors [3][5]. Group 2: Closed-End Funds (CEFs) Dynamics - CEFs operate differently from ETFs or mutual funds, raising a fixed pool of capital at launch, which can lead to inefficiencies in trading [4]. - When investors sell CEF shares without considering underlying assets, discounts can widen, creating buying opportunities for savvy investors [4][7]. Group 3: BMEZ Fund Characteristics - BMEZ currently yields 9.2% and trades at an 11% discount to its net asset value (NAV), indicating a potential buying opportunity [7][12]. - The fund's portfolio includes biotech and medical device companies that may benefit from a favorable regulatory environment [6][8]. Group 4: Key Holdings and Performance - Alnylam (ALNY), a top holding in BMEZ, focuses on innovative RNA interference therapies and has seen significant stock gains under previous administration policies [8][9]. - Veeva Systems (VEEV), another key holding, has also performed well historically, benefiting from a favorable mergers and acquisitions environment [9][10]. - Dexcom (DXCM), the third largest holding, produces continuous glucose monitors and has experienced substantial stock growth [11]. Group 5: Future Outlook - The current administration's policies may support the healthcare sector, particularly for companies in BMEZ's portfolio, which could lead to further growth [12].

Core Insights - Hunterbrook Media released a report alleging that DexCom Inc. sold an "adulterated" glucose monitoring device, the G7, which underwent unauthorized design changes leading to accuracy issues [1][6] - The company has faced increased scrutiny from the FDA, executive departures, and a rise in patient complaints, indicating deeper challenges within DexCom [2][8] Group 1: Product Issues - A surprise FDA inspection revealed that DexCom made unauthorized changes to the G7 device, resulting in worse accuracy [1][6] - Reports indicate that many patients are reverting to the older G6 model or switching to competitors due to severe consequences from inaccurate G7 readings [3][4] - Internal documents show that DexCom altered a critical sensor coating without regulatory clearance, leading to a spike in complaints [6] Group 2: Financial and Market Impact - DexCom has been scrutinized for accounting practices that artificially boosted earnings, raising concerns about potential future financial surprises [7] - The company's stock price fell by 4.54% to $72.97, trading within a 52-week range of $57.52 to $93.25 [8] Group 3: Leadership and Culture - Executive departures, including the sudden exit of CEO Kevin Sayer, have compounded the company's challenges [8] - Former employees have described a corporate culture that prioritized profits over patient safety, with claims that the G7 was rushed to market [4][5]

Group 1: Palo Alto Networks (PANW) - Palo Alto Networks reported a revenue increase of 15% year on year to US$9.2 billion for FY2025, with operating profit rising 81.7% to US$1.2 billion [2] - Profit before tax climbed 61.5% year on year to US$1.6 billion, and free cash flow increased by 12% to US$3.47 billion [3] - The company announced the acquisition of CyberArk Software for approximately US$25 billion, at a 26% premium to its share price [4] Group 2: Ecolab (ECL) - Ecolab's revenue remained flat at US$7.7 billion for 1H 2025, while operating profit increased by 7.7% to US$1.27 billion [5] - The company generated a free cash flow of US$616.6 million and declared a cash dividend of US$0.65, which is 14% higher than the previous year [6] - Ecolab expects earnings per share for 2025 to be between US$2.02 and US$2.12, reflecting a year-on-year increase of 10% to 16% [7] Group 3: DexCom (DXCM) - DexCom reported a revenue increase of nearly 14% year on year to US$2.2 billion for 1H 2025, with operating profit climbing 33.7% to US$346.3 million [8] - The company generated a free cash flow of US$305.5 million, despite a slight dip in net profit to US$285.2 million due to a higher tax bill [9] - The diabetes market is projected to grow significantly, with the number of sufferers expected to rise from 589 million in 2024 to 853 million by 2030 [9][10] Group 4: HubSpot (HUBS) - HubSpot's revenue increased by 17.6% year on year to US$1.47 billion for 1H 2025, with gross profit improving by 16.3% to US$1.24 billion [11] - The company achieved a free cash flow of US$259.8 million, which is 28.7% higher than the previous year [12] - HubSpot's customer count grew by 18% year on year to 267,982, and calculated billings increased by 26% to US$814.3 million [12]

Group 1: Company Overview - DexCom, Inc. is a leading provider of continuous glucose monitoring (CGM) devices, serving millions of individuals managing Type 1 and Type 2 diabetes, as well as those tracking glucose for wellness purposes [2] - Founded in 1999, DexCom pioneered accurate, real-time glucose monitoring, shifting the standard of care away from periodic finger pricks [2] - The company's competitive edge lies in product performance and integration across platforms, with devices like G6, G7, and Stelo offering seamless connectivity compared to competitors [2] Group 2: Business Model and Financial Performance - DexCom's business model is highly lucrative, with hardware representing only 5% of revenue and disposable sensors accounting for 95%, supported by industry-leading retention rates [3] - Despite its strong business model, the stock has underperformed over the past five years, reflecting a negative 20% total return due to growing competition and market pressures [3] - The company faces challenges from Abbott's low-cost FreeStyle Libre platform and Medtronic's investments in next-generation CGM, alongside potential reduced demand from Type 2 patients due to the adoption of GLP-1 drugs [3] Group 3: Market Opportunities - CGM penetration remains low in key populations, including over 100 million Type 2 diabetics and prediabetics in the U.S., with expanding insurance coverage enhancing adoption potential [4] - International markets, such as Japan and Saudi Arabia, are underpenetrated, offering additional growth opportunities [4] - The entry into over-the-counter and wellness markets with Stelo may create new revenue streams for the company [4] Group 4: Investment Thesis - The combination of a high-margin, sticky business model, innovation leadership, and underpenetrated markets provides a compelling risk/reward profile for investors [4] - Previous bullish theses highlighted product innovation, Type 2 diabetes expansion, and user growth despite margin pressures, although the stock has depreciated about 6% since then due to competition and cost headwinds [5] - The current thesis emphasizes reimbursement gains and platform integration, while also acknowledging risks associated with GLP-1 drugs [5]

Group 1 - Alnylam Pharmaceuticals Inc is focused on developing therapies based on RNA interference technology, which has shown promise in treating rare genetic diseases [1] - DexCom Inc specializes in continuous glucose monitoring systems for diabetes management, indicating a growing demand for innovative health technology solutions [1] - Veeva Systems Inc Class A provides cloud-based software solutions for the global life sciences industry, highlighting the increasing reliance on digital transformation in healthcare [1] Group 2 - BlackRock Health Sciences Trust II is an investment vehicle that targets companies in the health sciences sector, reflecting investor interest in healthcare as a resilient investment area [1]

Core Insights - DexCom, Inc. (NASDAQ:DXCM) has shown strong financial performance, exceeding revenue and EPS estimates in Q2 2025, with revenue of $1.16 billion, a 15.21% year-over-year increase, and EPS of $0.48, surpassing expectations by $0.04 [1][2] Financial Performance - The company reported a revenue of $1.16 billion, which is up 15.21% year-over-year and exceeded consensus estimates by $32.49 million [1] - The US revenue segment grew by 15%, while the International segment saw a 7% year-over-year growth [2] Analyst Sentiment - Several analysts have maintained a bullish outlook on DexCom, with price targets indicating significant upside potential; Argus Research set a target of $100, Bernstein at $98, and Piper Sandler also at $100, suggesting a 35.5% upside from current levels [3]

Core Insights - DexCom, Inc. is set to showcase new product features and present new evidence demonstrating the benefits of its glucose biosensing technology for individuals with all types of diabetes at the 61st annual European Association for the Study of Diabetes (EASD) Conference [1] Company Developments - The upcoming EASD Conference serves as a significant platform for DexCom to highlight its latest product innovations and clinical data [1]